BerGenBio

BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference

- Presentation available September 11, 2023 on BGBIO website -

BERGEN, Norway, September 11, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical

-stage biopharmaceutical company developing novel, selective AXL kinase

inhibitors for Non-Small Cell Lung Cancer (NSCLC), announcedtoday that the

Company will participate in the H.C. Wainwright 25th Annual Global Investment

Conference held in New York City, September 11-13, 2023.

Chief Executive Officer Martin Olin will provide an update on BerGenBio

including a review of clinical data substantiating the role of selective AXL

inhibition with its lead molecule bemcentinib in cancer and describing on-going

activities in the treatment of first line metastatic NSCLC patients with STK11

mutations - a known prognostic factor in poorer response to current standard of

care therapies.

The presentation used in the webcast will be uploaded to the investor section of

the Company's websitewww.bergenbio.com/investors/presentations at time of

presentation, September 11, 7.00am ET (13:00 CEST).

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal